Jefferies Financial Group Inc. Buys New Holdings in The Chemours Company $CC

Jefferies Financial Group Inc. bought a new position in The Chemours Company (NYSE:CC) in the 2nd quarter, HoldingsChannel.com reports. The firm bought 779,545 shares of the specialty chemicals company’s stock, valued at approximately $15,996,000.

A number of other institutional investors have also recently bought and sold shares of the business. Parallel Advisors LLC boosted its stake in Chemours by 10.9% during the first quarter. Parallel Advisors LLC now owns 5,366 shares of the specialty chemicals company’s stock worth $118,000 after buying an additional 527 shares in the last quarter. Oregon Public Employees Retirement Fund raised its stake in shares of Chemours by 1.8% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 34,300 shares of the specialty chemicals company’s stock valued at $404,000 after buying an additional 600 shares in the last quarter. Man Group plc lifted its holdings in shares of Chemours by 0.4% during the 2nd quarter. Man Group plc now owns 271,108 shares of the specialty chemicals company’s stock worth $3,104,000 after acquiring an additional 979 shares during the period. Rothschild Investment LLC boosted its position in shares of Chemours by 87.0% during the 4th quarter. Rothschild Investment LLC now owns 2,698 shares of the specialty chemicals company’s stock valued at $32,000 after acquiring an additional 1,255 shares in the last quarter. Finally, Abel Hall LLC boosted its position in shares of Chemours by 12.6% during the 1st quarter. Abel Hall LLC now owns 12,267 shares of the specialty chemicals company’s stock valued at $270,000 after acquiring an additional 1,369 shares in the last quarter. Institutional investors and hedge funds own 76.26% of the company’s stock.

Chemours Price Performance

Chemours stock opened at $15.85 on Friday. The company has a debt-to-equity ratio of 18.98, a quick ratio of 0.88 and a current ratio of 1.66. The firm has a market cap of $2.39 billion, a P/E ratio of -8.30 and a beta of 1.43. The business’s fifty day moving average is $17.52 and its two-hundred day moving average is $20.00. The Chemours Company has a 52 week low of $10.44 and a 52 week high of $28.67.

Chemours (NYSE:CC) last announced its earnings results on Tuesday, August 4th. The specialty chemicals company reported $0.42 EPS for the quarter, missing the consensus estimate of $0.49 by ($0.07). Chemours had a positive return on equity of 60.64% and a negative net margin of 5.00%.The business had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.65 billion. During the same quarter in the previous year, the company posted ($2.54) EPS. Chemours’s revenue for the quarter was down 1.5% on a year-over-year basis. Equities research analysts forecast that The Chemours Company will post 0.87 earnings per share for the current fiscal year.

Chemours Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Friday, August 14th will be issued a dividend of $0.0875 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $0.35 dividend on an annualized basis and a yield of 2.2%. Chemours’s dividend payout ratio is currently -18.32%.

Insiders Place Their Bets

In related news, CFO Shane Hostetter bought 3,350 shares of Chemours stock in a transaction dated Thursday, August 6th. The shares were bought at an average cost of $14.94 per share, for a total transaction of $50,049.00. Following the completion of the transaction, the chief financial officer owned 102,698 shares of the company’s stock, valued at approximately $1,534,308.12. This trade represents a 3.37% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Calderon Gerardo Familiar purchased 1,935 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The shares were bought at an average cost of $15.53 per share, for a total transaction of $30,050.55. Following the completion of the purchase, the insider directly owned 58,547 shares of the company’s stock, valued at $909,234.91. The trade was a 3.42% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 8,663 shares of company stock valued at $130,601 in the last 90 days. 0.85% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research analysts recently issued reports on CC shares. Weiss Ratings lowered shares of Chemours from a “sell (d)” rating to a “sell (d-)” rating in a research report on Thursday, August 6th. Zacks Research downgraded Chemours from a “strong-buy” rating to a “strong sell” rating in a report on Tuesday, August 11th. BMO Capital Markets lowered their price objective on Chemours from $26.00 to $18.00 and set an “outperform” rating on the stock in a research note on Thursday, August 13th. Alembic Global Advisors reissued an “overweight” rating and issued a $30.00 target price on shares of Chemours in a report on Wednesday, May 13th. Finally, Truist Financial dropped their target price on Chemours from $30.00 to $24.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Five research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $20.10.

About Chemours

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.